As it still remains to be determined if administration of a complement inhibitor after myocardial ischemia and before reperfusion is effective, we may have to leave the beaten path and “should strike out on new paths” (John D. Rockefeller, 1839–1937) avoiding single-target interventions and investigate pleiotropic compounds such as the natural inhibitor of the lectin pathway, C1INH, that also interferes with other important pro-inflammatory pathways. The gene discussed is SERPING1; the disease is myocardial ischemia.